Avalo Therapeutics (AVTX) Net Equity Issued and Repurchased (2016 - 2023)

Avalo Therapeutics (AVTX) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $25.9 million in Q3 2023.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $25.9 million in Q3 2023, while the trailing twelve-month figure through Dec 2024 was $25.9 million (changed 0.0% YoY) and the FY2025 annual result came in at $14.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased improved to $25.9 million in Q3 2023, from $37.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $35.4 million in Q2 2020 to a low of -$37.0 in Q3 2020.
• A 3-year average of $14.1 million and a median of $9.0 million in 2019 frame the typical range for Net Equity Issued and Repurchased.